September 10th 2025, 9:00pm
Living with follicular lymphoma, I’ve learned many assumptions about cancer, remission and treatment side effects don’t reflect the reality I face.
August 8th 2025, 3:00pm
Epkinly with Rituxan and Revlimid, compared to Rituxan and Revlimid alone, reduced risk of progression or death by 79%.
July 17th 2025, 9:00pm
When asked to choose a word other than “survivor” to describe myself, I chose “person” because cancer does not define who I am.
April 30th 2025, 5:06pm
Four years after remission from follicular lymphoma, ongoing fear of relapse, lingering symptoms, and life stressors continue to weigh heavily on me.
April 22nd 2025, 4:54pm
It’s spring, a time for new beginnings following a cancer diagnosis; however, I have an ongoing issue that I can’t dismiss.
March 21st 2025, 5:00pm
Life after treatment for follicular lymphoma brings long-term physical and emotional challenges, including immune system impacts and lasting social effects.
March 14th 2025, 4:00pm
Dr. Deepa Jagadeesh discusses Ordspono's potential FDA approval for relapsed/refractory follicular lymphoma, highlighting its manageable toxicity and low CRS rate.
March 7th 2025, 6:00pm
Living with follicular lymphoma, I challenge common misconceptions about cancer, highlighting the unique and varied experiences of patients with cancer.
February 18th 2025, 6:00pm
My annual scan showed no cancer recurrence, but revealed some minor issues related to aging and potential fibroids, requiring monitoring and follow-up.
January 2nd 2025, 6:00pm
Despite being declared cancer-free after initial treatment, I grapple with survivor's guilt, questioning why my lymphoma responded to therapy while others did not.
Thanking My Support System From My Cancer Journey
Ibtrozi May Address Unmet Needs In ROS1-Positive Non-Small Cell Lung Cancer
Actively Recruiting Trials for Lung, Biliary, AML and Small Cell Cancer
The Lessons of the Woods